Cargando…
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
SIMPLE SUMMARY: The Bcl2 inhibitor venetoclax is a breakthrough therapy in acute myeloid leukemia (AML). We show that venetoclax induces caspase-dependent degradation of AMPK, a central regulator of cellular energy metabolism, with implications in the anti-Leukemic activity of venetoclax in AML. ABS...
Autores principales: | Legrand, Noémie, Pradier, Amandine, Poulain, Laury, Mouche, Sarah, Birsen, Rudy, Larrue, Clément, Simonetta, Federico, Tamburini, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656606/ https://www.ncbi.nlm.nih.gov/pubmed/34885077 http://dx.doi.org/10.3390/cancers13235966 |
Ejemplares similares
-
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia
por: Larrue, Clement, et al.
Publicado: (2023) -
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
por: Chapuis, Nicolas, et al.
Publicado: (2019) -
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021) -
Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023) -
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
por: Han, Lina, et al.
Publicado: (2020)